Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The head of the United States Food and Drug Administration’s vaccine advisory committee has recused herself from the panel due to her involvement in supervising the clinical trial of Moderna Inc’s COVID-19 vaccine, Reuters reported Wednesday.

FDA Vaccine Committee Head Steps Aside Over Conflict Of Interest With Moderna Role

Canada just ordered 20 million doses of Moderna’s Covid-19 vaccine. That’s excellent news for anyone who owns MRNA stock, Canadians included.

Aggressive Investors Have No Excuse for Not Owning Moderna

MRNA stock is up 25% since early September on renewed hope the company gets its Covid-19 vaccine through clinical trials by November.
The post Why Moderna May Be Ready to Deliver an October Surprise appeared first on InvestorPlace.

Why Moderna May Be Ready to Deliver an October Surprise

AstraZeneca

Inovio Pharmaceuticals

Novavax

Pfizer

Today, investors are better prepared to choose potential winners.

Now Is the Perfect Time to Invest in Coronavirus Vaccine Stocks

BioNTech SE

Vir Biotechnology

Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.

4 Biotechs That Have More Than Doubled Thanks to Coronavirus

Snowflake

Tesla

Now is the time to take profits on these three high-flying growth stocks in case of a stock market crash.

3 Absurdly Overvalued Stocks to Avoid During a Market Crash

Moderna looks like it has a winner with its Covid-19 vaccine. MRNA stock could make $35 billion if it delivers 1 billion doses, making its $26 billion market cap look cheap.

Moderna Stock Looks Like a Winner as the Covid-19 Vaccine Race Loosens

Optimism that vaccines are on the way to end the coronavirus pandemic has been a major factor in this year’s U.S. stock resurgence.

COVID-19 vaccine verdicts loom as next big market risk

Moderna’s R&D day was a non-event, while upcoming clinical data posts may re-ignite MRNA stock buying.
The post Here’s Why Moderna Shares May Blast Higher Over the Next Few Weeks appeared first on InvestorPlace.

Here’s Why Moderna Shares May Blast Higher Over the Next Few Weeks

Adverse event(s?) with AstraZeneca/Oxford University Phase 3 trial need more clarity for public confidence; the adverse event(s?) came after the second dose of the vaccine.

COVID-19 Vaccine Car Crash

The CEO of Covid-19 vaccine developer Moderna Inc. (NASDAQ:MRNA) could be getting a little ahead of himself.

Moderna CEO: It's All or Nothing

Investors came back to the biotech's shares early this week. But will the optimism stick?

Are the Gains Over for This Early Leader in the Coronavirus Vaccine Race?

The biotech is ramping up production ahead of the results from its late-stage clinical study of mRNA-1273.

Moderna Plans to Produce 20 Million Doses of Its COVID-19 Vaccine Candidate in 2020

Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) held a virtual R&D event Thursday, showcasing its portfolio and key therapeutic areas.

3 Moderna Analyst Takes On The Coronavirus Vaccine Developer's Pipeline

There's also one other candidate that's hot on their heels.

3 Coronavirus Vaccines in Phase 3 Clinical Studies: How They Stack Up Against Each Other

Vertex Pharmaceuticals

This is the companies' second project to tackle the lung disease.

Beyond Coronavirus: Moderna Teams Up With Vertex on Cystic Fibrosis Therapy

"My only hope is that Dr. Hahn and the political appointees in the FDA stand up and basically say, 'No, we cannot have political pressure lead the FDA into making a decision,'" said Dr.

Moderna trial investigator worries about political pressure in vaccine approval process

Investors were trying to find their footing with the stock after a series of updates.

Why Moderna Was So Volatile on Thursday

Netflix

Zoom Video

The stock market recovery has been astonishing which makes for a good time to look for trouble. Thus, here are three stocks to short now.

3 Stocks to Short Near All-Time Highs

Biotech firm Moderna expects to know by November whether its coronavirus vaccine is effective at warding off the deadly disease, CEO Stephane Bancel said Thursday. Massachusetts-based Moderna says it has enrolled 25,296 people in the late-stage clinical trial of its COVID-19 vaccine that kicked off in July, one of three such studies currently underway in.

Moderna expects COVID-19 vaccine trial results by November, CEO says

Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) is issuing updates Thursday from its virtual R&D day.

COVID-19 Vaccine Developer Moderna In The Spotlight With R&D Day, 2 Collaborations

MRNA stock is rallying Thursday on news Moderna will wrap up its late-stage trials by the end of the year. Here's why it matters.

MRNA Stock: Moderna Rallies Thursday on Vaccine Timeline News

Moderna, at its annual R&D Day, updated progress on its Covid-19 vaccine and drug pipeline, and said it would work to develop a seasonal flu vaccine; MRNA stock looked to continue win streak.
The post Moderna Updates Progress On Covid-19 Vaccine; Eyes Flu Vaccine appeared first on Investor's Business Daily.

Moderna Updates Progress On Covid-19 Vaccine; Eyes Flu Vaccine

Moderna noted that vaccines generally reduce people's risk of getting influenza by 40% to 60% compared with people who aren't inoculated. 

Moderna says it will begin developing a vaccine for seasonal flu

You'll have a much better shot at getting a shot next year.

News for Moderna Stock (MRNA)